Astellas Pharma
(OTC) ALPMF
Astellas Pharma Financials at a Glance
Market Cap
$24.45B
Revenue (TTM)
$2.15T
Net Income (TTM)
$293.07B
EPS (TTM)
$1.08
P/E Ratio
12.61
Dividend
$0.51
Beta (Volatility)
0.04 (Low)
Dividend
$0.51
Beta (Volatility)
0.04 (Low)
Price
$15.70
Volume
653
Open
$14.07
Price
$15.70
Volume
653
Open
$14.07
Previous Close
$13.65
Daily Range
$14.07 - $15.70
52-Week Range
$9.34 - $17.85
Dividend
$0.51
Beta (Volatility)
0.04 (Low)
Price
$15.70
Volume
653
Open
$14.07
Previous Close
$13.65
Daily Range
$14.07 - $15.70
52-Week Range
$9.34 - $17.85
ALPMF News
A $20 Billion Sweet Spot in Biotech
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Astellas Pharma
Industry
Pharmaceuticals
Sector
Health CareEmployees
13,643
CEO
Naoki Okamura
Website
www.astellas.comHeadquarters
Tokyo, 103-8411, JP
ALPMF Financials
Key Financial Metrics (TTM)
Gross Margin
76%
Operating Margin
19%
Net Income Margin
14%
Return on Equity
18%
Return on Capital
17%
Return on Assets
8%
Earnings Yield
7.93%
Dividend Yield
3.73%
Payout Ratio
46.68%
Stock Overview
Market Cap
$24.45B
Shares Outstanding
1.79B
Volume
653
Avg. Volume
5.19K
Financials (TTM)
Gross Profit
$1.60T
Operating Income
$422.34B
EBITDA
$618.16B
Operating Cash Flow
$569.82B
Capital Expenditure
$58.09B
Free Cash Flow
$511.73B
Cash & ST Invst.
$283.38B
Total Debt
$569.51B
Astellas Pharma Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$541.31B
+17.9%
Gross Profit
$411.07B
+7.5%
Gross Margin
75.94%
N/A
Market Cap
$24.45B
N/A
Market Cap/Employee
$1.66M
N/A
Employees
14,754
N/A
Net Income
$43.89B
-41.4%
EBITDA
$129.02B
+26.8%
Quarterly Fundamentals
Net Cash
$286.14B
+53.3%
Accounts Receivable
$766.56B
+21.2%
Inventory
$333.10B
+12.1%
Long Term Debt
$322.01B
-43.0%
Short Term Debt
$247.50B
-7.1%
Return on Assets
8.17%
N/A
Return on Invested Capital
17.24%
N/A
Free Cash Flow
$189.72B
+107.6%
Operating Cash Flow
$206.42B
+104.2%